| Dec 17, 2025 | T-Curx | $20.0M Curx - Series A | Dr. Aristotelis Nastos | Monika Steger, i&i Biotech Fund |
| Mar 14, 2024 | Tubulis GmbH | $140.1M Series B | Christoph Broja, Kanishka Pothula | Sofia Ioannidou, Bayern Kapital, coparion, Deep Track Capital, Evotec, Frazier Life Sciences, Caroline Goddeeris, High-Tech Grunderfonds, OCCIDENT, Seventure Partners |
| Nov 14, 2023 | Eyebiotech | $65.0M Series A Extension | Michael Ross, Andreas Wallnofer | Bain Capital Life Sciences, Jeito Capital, MRL Ventures Fund, Bernard Davitian, Samsara BioCapital, SV Health Investors, Christine Brennan |
| Sep 20, 2023 | TOLREMO therapeutics | $38.0M Series A | BioMedPartners | Francesco Hofmann |
| Dec 6, 2022 | Tricares | $53.6M Series C | Frederik Groenewegen | Sofia Ioannidou, Dr. Georg Ried, Credit Mutuel Innovation, Go Capital, Karista, Regina Hodits |
| May 1, 2022 | Tubulis | $63.0M Series B | Andera Partners | 5AM Ventures, Abingworth, Coparion, EQT Life Sciences, Frazier Healthcare Partners, Hakan Goker, Third Rock Ventures, Venrock, Versant Ventures, Bayern Kapital, Valentin Piech, Thomas Hanke, Jan Van den Bossche, High-Tech Grunderfonds, OCCIDENT, Seventure Partners |
| Mar 11, 2022 | Scenic Biotech | $31.0M Series A | Michael Wacker, Stephan Christgau, Stephane Verdood | BioGeneration Ventures, INKEF Capital, Oxford Science Enterprises |
| Mar 1, 2022 | Precirix | $88.0M Series B | Forbion, INKEF Capital, Sabine Dandiguian | Aglaia BioMedical Ventures, Keno Gutierrez, Novartis Venture Fund, Pfizer Venture Investments, Pontifax Venture Capital, Gimv, HealthCap, Novo Holdings, V-Bio Ventures |
| Aug 1, 2021 | Cardior Pharmaceuticals | $75.0M Series B | INKEF Capital | Bristol Myers Squibb, coparion, Fund+, Hadean Ventures, High-Tech Grunderfonds, Karin Kleinhans, Sunstone Capital |
| Jul 29, 2021 | Topas Therapeutics | $21.3M Series B Extension | — | Boehringer Ingelheim, EMBL Ventures, Epidarex Capital, Werner Lanthaler, Gimv, Vesalius Biocapital |
| Oct 19, 2020 | Topas Therapeutics | $25.9M Series B | Michael Wacker, Marc Lohrmann | — |
| Jul 1, 2020 | Tubulis | $12.0M Series A | Michael Wacker, High-Tech Grunderfonds | Andera Partners, Coparion, EQT Life Sciences, Frazier Healthcare Partners, Third Rock Ventures, Venrock, Bayern Kapital, OCCIDENT, Seventure Partners |
| Jun 10, 2020 | TOLREMO therapeutics | $5.0M Series A Extension | Altos Ventures, BioMedPartners | Redalpine, Z%C3%BCrcher%20Kantonalbank |
| Feb 1, 2020 | Azafaros | $27.0M Series A | Forbion | Edward Van Wezel, BGV (BioGeneration Ventures), Andreas Wallnoefer |
| Dec 1, 2019 | ImmunOs Therapeutics | $15.0M Series A | BioMedPartners | Angel investor, BackBone Ventures, Pfizer Venture Investments, Samsara BioCapital, Balaji Srinivasan, Daniel Vasella |
| Sep 1, 2019 | Inotrem | $43.0M Series B | Jason Dinges | Soffinova Partners, Andera Partners, Invus |
| May 1, 2019 | Alentis Therapeutics | $12.3M Series A | BioMedPartners, Pureos Bioventures | — |
| Nov 1, 2018 | Precirix | $42.0M Series A | Karl Nagler, Christina Takke | Abingworth, Forbion, HealthCap, Novartis Venture Fund, Pfizer Venture Investments, Pontifax Venture Capital, Morten Graugaard Døssing |
| Sep 24, 2018 | TOLREMO therapeutics | $9.4M Series A | Andreas Wallnoefer | Altos Ventures, Redalpine, Z%C3%BCrcher%20Kantonalbank |
| Jun 1, 2018 | Tricares | $26.0M Series B | Andera Partners, Wellington Partners, Thomas Möller | Emilie LIDOME, Leila Nicolas Guerlain, Catherine Boule |
| Dec 1, 2017 | Hookipa Pharma | $60.0M Series C | — | Boehringer Ingelheim Venture Fund, Soffinova Partners, Boehringer Ingelheim, Forbion, Gilead Sciences, HBM Partners, Hillhouse Capital, Sirona Capital, Takeda Ventures |
| Sep 1, 2017 | Amal Therapeutics | $10.0M Series B | Andreas Wallnoefer, Knut Elbers, Helsinn | Boehringer Ingelheim Venture Fund, High-Tech Grunderfonds, Schroder Adveq, VI Partners |
| May 11, 2017 | Cardior Pharmaceuticals | $16.3M Series A | BioMedPartners, Boehringer Ingelheim, Bristol Myers Squibb, High-Tech Grunderfonds, Joachim Rothe | — |
| May 27, 2016 | Aleva Neurotherapeutics | $18.0M Series C | Anthony Borowicz | Banexi Ventures Partners, BB Biotech Ventures, Forrestal Capital, Initiative Capital Romandie, Kinled Holding |
| Sep 4, 2015 | Aleva Neurotherapeutics | $16.1M Other Equity | — | Banexi Ventures Partners, BB Biotech Ventures, Initiative Capital Romandie |
